The Global Gene Synthesis Market was valued at USD 951.9 million in 2024 and is estimated to grow at a CAGR of 16.9% to reach USD 4.6 billion by 2034.
Market expansion is propelled by the rise of synthetic biology, continual progress in DNA synthesis technologies, and growing investments in genomics research worldwide. The expanding use of personalized medicine and biomarker development is also increasing the demand for high-precision gene construction tools. The gene synthesis industry provides essential solutions for pharmaceutical companies, biotechnology firms, academic research centers, and healthcare technology developers by offering custom gene synthesis, DNA library creation, and advanced cloning services. These solutions improve the efficiency of genetic engineering workflows, drug discovery studies, and molecular diagnostics. Automated synthesis platforms and sophisticated error-correction technologies have enhanced accuracy while reducing cost and turnaround time, making gene synthesis widely accessible. Increased government and private funding for large-scale genomics initiatives supports applications in disease modeling, agriculture, and industrial biotechnology. Growing utilization of synthetic genes in antibody engineering, vaccine development, and therapeutic design continues to push the industry forward. The post-pandemic landscape has further reinforced the importance of rapid synthetic gene production for accelerated therapeutic innovation.
The solid-phase synthesis segment held 58.6% share in 2024, driven by its scalability, high precision, and suitability for generating long DNA sequences for both research and commercial use. Its stepwise nucleotide addition method enhances reliability and purification efficiency, making it a preferred synthesis technique.
The antibody DNA synthesis segment accounted for a 46.4% share in 2024 and is projected to reach USD 2.2 billion during the forecast period. Growth is driven by rising demand for monoclonal antibody therapies used across cancer treatment, immune system disorders, infectious diseases, and various rare conditions. This surge has increased the need for custom-designed antibody genes to accelerate therapeutic development pipelines.
North America Gene Synthesis Market held a 40.3% share in 2024. The region’s leadership is supported by major biotechnology and pharmaceutical companies, strong research ecosystems, and significant investment in genomics and synthetic biology. Supportive regulatory structures and advanced clinical research capabilities continue to elevate the adoption of gene synthesis technologies.
Prominent companies participating in the Global Gene Synthesis Market include Azenta, Inc. (GENEWIZ), BIOMATIK, Bio Basic Inc., BIONEER CORPORATION, Gene Universal Inc., Eurofins Scientific SE, Integrated DNA Technologies, Inc., GenScript, Macrogen, Inc., ProMab Biotechnologies, Inc., OriGene Technologies, Inc., ProteoGenix, Synbio Technologies, Thermo Fisher Scientific Inc., and Twist Bioscience Corporation. Companies in the Gene Synthesis Market are strengthening their competitive position by scaling up automated synthesis platforms, improving error-correction capabilities, and expanding their custom gene design services. Many firms are forming strategic partnerships with pharmaceutical and biotechnology companies to integrate synthesis technologies directly into drug discovery and antibody engineering workflows. Investments in high-throughput systems and cloud-based sequence design tools are enabling faster project turnaround and greater volume capacity.
This product will be delivered within 2-4 business days.
Market expansion is propelled by the rise of synthetic biology, continual progress in DNA synthesis technologies, and growing investments in genomics research worldwide. The expanding use of personalized medicine and biomarker development is also increasing the demand for high-precision gene construction tools. The gene synthesis industry provides essential solutions for pharmaceutical companies, biotechnology firms, academic research centers, and healthcare technology developers by offering custom gene synthesis, DNA library creation, and advanced cloning services. These solutions improve the efficiency of genetic engineering workflows, drug discovery studies, and molecular diagnostics. Automated synthesis platforms and sophisticated error-correction technologies have enhanced accuracy while reducing cost and turnaround time, making gene synthesis widely accessible. Increased government and private funding for large-scale genomics initiatives supports applications in disease modeling, agriculture, and industrial biotechnology. Growing utilization of synthetic genes in antibody engineering, vaccine development, and therapeutic design continues to push the industry forward. The post-pandemic landscape has further reinforced the importance of rapid synthetic gene production for accelerated therapeutic innovation.
The solid-phase synthesis segment held 58.6% share in 2024, driven by its scalability, high precision, and suitability for generating long DNA sequences for both research and commercial use. Its stepwise nucleotide addition method enhances reliability and purification efficiency, making it a preferred synthesis technique.
The antibody DNA synthesis segment accounted for a 46.4% share in 2024 and is projected to reach USD 2.2 billion during the forecast period. Growth is driven by rising demand for monoclonal antibody therapies used across cancer treatment, immune system disorders, infectious diseases, and various rare conditions. This surge has increased the need for custom-designed antibody genes to accelerate therapeutic development pipelines.
North America Gene Synthesis Market held a 40.3% share in 2024. The region’s leadership is supported by major biotechnology and pharmaceutical companies, strong research ecosystems, and significant investment in genomics and synthetic biology. Supportive regulatory structures and advanced clinical research capabilities continue to elevate the adoption of gene synthesis technologies.
Prominent companies participating in the Global Gene Synthesis Market include Azenta, Inc. (GENEWIZ), BIOMATIK, Bio Basic Inc., BIONEER CORPORATION, Gene Universal Inc., Eurofins Scientific SE, Integrated DNA Technologies, Inc., GenScript, Macrogen, Inc., ProMab Biotechnologies, Inc., OriGene Technologies, Inc., ProteoGenix, Synbio Technologies, Thermo Fisher Scientific Inc., and Twist Bioscience Corporation. Companies in the Gene Synthesis Market are strengthening their competitive position by scaling up automated synthesis platforms, improving error-correction capabilities, and expanding their custom gene design services. Many firms are forming strategic partnerships with pharmaceutical and biotechnology companies to integrate synthesis technologies directly into drug discovery and antibody engineering workflows. Investments in high-throughput systems and cloud-based sequence design tools are enabling faster project turnaround and greater volume capacity.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Method, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Services, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Complexity, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
The companies featured in this Gene Synthesis market report include:- Azenta, Inc. (GENEWIZ)
- Bio Basic Inc.
- BIOMATIK
- BIONEER CORPORATION
- Eurofins Scientific SE
- Gene Universal Inc.
- GenScript
- Integrated DNA Technologies, Inc.
- Macrogen, Inc.
- OriGene Technologies, Inc.
- ProMab Biotechnologies, Inc.
- ProteoGenix
- Synbio Technologies
- Thermo Fisher Scientific Inc.
- Twist Bioscience Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | November 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 951.9 Million |
| Forecasted Market Value ( USD | $ 4600 Million |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
